2004
DOI: 10.1016/s0377-1237(04)80003-0
|View full text |Cite
|
Sign up to set email alerts
|

Routine Cyclosporine concentration - C2 level Monitoring. Is it helpful during the early post Transplant Period?

Abstract: In our study CSA levels, trough and peak showed significant inter patient variability. The trough and C2 concentration levels did not correlate with the episodes of acute rejection. We conclude that in a triple drug regimen with fixed dosing schedules routine trough CSA level monitoring is not helpful in the acute post renal transplant period.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2018
2018
2023
2023

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(3 citation statements)
references
References 8 publications
0
3
0
Order By: Relevance
“…However, Einecke and colleagues recently showed that C 2 monitoring is limited as a predictor for the risk of rejection or CsA toxicity [20]. Narula and colleagues could not define a correlation between CsA trough levels and episodes of acute rejection [21]. In all these studies the relationship between CsA and calculated AUC with acute rejection was investigated.…”
Section: Discussionmentioning
confidence: 99%
“…However, Einecke and colleagues recently showed that C 2 monitoring is limited as a predictor for the risk of rejection or CsA toxicity [20]. Narula and colleagues could not define a correlation between CsA trough levels and episodes of acute rejection [21]. In all these studies the relationship between CsA and calculated AUC with acute rejection was investigated.…”
Section: Discussionmentioning
confidence: 99%
“…The results of the present clinical trial demonstrated that the C2 levels exhibited a good correlation with the measured AUC 0-4 h value, confirming that CsA monitoring at C2 not only accurately reflected the drug absorption but the implementation of this strategy also reduces cost and assessment time in the long-term management of HT recipients. While monitoring at C2 has been applied for HT recipients in clinical practice (12,24), efficacy of this type of monitoring remains controversial (25)(26)(27). To verify the feasibility of the C2 strategy in therapeutic drug monitoring, a regression analysis was employed to evaluate the correlation between the CsA level at C2 and the AUC 0-4 h , which was during the absorption phase of CsA in the recipients.…”
Section: Discussionmentioning
confidence: 99%
“…Table 3 shows the detailed validation results and the missing parameter data of other neutral drugs. Most neutral drugs that underwent a validation study have an LLOQ concentration below the plasma/serum concentration range of their drugs, except for everolimus, perampanel, and sirolimus [ 16 , 53 , 61 , 97 , 98 , 99 , 100 , 101 , 102 , 103 , 104 , 105 , 106 ]. Everolimus has an LLOQ of 0.02 µg/mL [ 61 ], whereas its concentration range is 0.003–0.008 µg/mL [ 100 ].…”
Section: Analytical Validation Of Volumetric Absorptive Microsampling...mentioning
confidence: 99%